Tu1578 IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS (PTS) WITH MAIN TRUNK AND/OR CONTRALATERAL PORTAL VEIN INVASION (VP4) TREATED WITH ATEZOLIZUMAB (ATEZO) + BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN A PH III STUDY